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OBJECTIVES: While 3-tier pharmacy copayment struc-
ture is the most common pharmacy beneﬁt design in
2002, limited published studies examine the value of such
beneﬁt design. This study evaluated the impact of chang-
ing from a 2-tier to 3-tier pharmacy beneﬁt on drug costs,
utilization and generic utilization rates of top 10 thera-
peutic classes.
METHODS: An employer group that has changed from
a 2-tier ($5/$10) to 3-tier pharmacy beneﬁt ($5/$15/$25)
in 6/2000 and a managed health plan that has similar 2-
tier pharmacy beneﬁt and membership base were chosen
respectively as the case and control for this study. Phar-
macy claims data 12 months pre- and 15 months post 
3-tier beneﬁt implementation was evaluated. Top 10 ther-
apeutic classes (TC ranked by total drug ingredient costs
spent) of the case were identiﬁed at baseline. For each TC,
net changes in drug ingredient costs per member per
month (PMPM), drug utilization per member per year
(PMPY) and generic utilization rates from baseline were
calculated and adjusted for inherent TC trends using the
control data.
RESULTS: During the 15-month follow-up period, reduc-
tion in PMPM costs occurred in 9 out of the 10 TC, with
an average PMPM reduction of $0.36 per TC. Dramatic
reductions in PMPM costs were observed on all TCs
within 3 months post-implementation of 3-tier beneﬁt;
however, all TCs (except for acne medications) showed
increase in PMPM costs toward baseline values during 
the rest of the study period. Only modest reduction 
(0.07 PMPY) in prescription utilization was observed.
Four TCs demonstrated marked improvement in average
generic utilization rates (cephalosporins 8.7%, calcium
channel blockers 6.2%, ACE inhibitors 5.0%, acne 
products 4.1%).
CONCLUSIONS: A 3-tier pharmacy beneﬁt can reduce
pharmacy expenditures and improve generic utilization
rates of common drug classes. Further research to evalu-
ate its impact on medical costs is warranted.
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INTER-INSTITUTIONAL VARIABILITY IN
PHARMACY COSTS, LENGTH OF STAY AND
MORTALITY ASSOCIATED WITH CARDIAC
TRANSPLANTATION AT ACADEMIC HEALTH
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OBJECTIVE: When ranked by inpatient pharmaceutical
cost, cardiac transplantation (DRG 103) consistently
appears among the top 10 DRGs in the University Health-
System Consortium (UHC) Clinical Database. This has
implications for pharmaceutical budgeting and managed
care contracting. The objective of this analysis was to
assess inter-institutional variability in clinical and eco-
nomic outcomes as measured by pharmacy costs, length
of stay and mortality among heart transplant patients in
UHC’s Pharmacy Clinical Database during calendar year
2000.
METHODS: Eight geographically diverse academic
health centers were identiﬁed retrospectively from all 20
UHC Pharmacy Clinical Database participants as having
submitted at least 5 heart transplant cases during calen-
dar year 2000. Institutions were assessed for variability
in pharmacy costs, length of stay (LOS) and mortality.
Data were compiled from hospital discharge summaries,
Uniform Billing Version 1992 data and charge descrip-
tion masters. Cost data were generated from converting
institution-speciﬁc charge data using a ratio of cost-to-
charges (RCC).
RESULTS: The total pharmaceutical cost for 232 patients
from 8 institutions [range = 5–96 patients/institution] was
$5,083,860. Across institutions the median pharmaceuti-
cal cost per patient, median LOS per patient and total
mortality rate were $11,509 (range = $5,697–$32,763),
22 days (range = 10.5 days–105 days), and 10.3% (range
= 0%–23.5%) respectively. Cardiovascular agents
(17.6%), biologic and immunologic agents (16.7%),
hematological agents (16.4%) and systemic anti-
infectives (10.7%) comprised over 60% of total phar-
maceutical cost. Variation in percent class cost of 
total pharmaceutical costs among institutions were
11.9%–28.4% in cardiovascular agents, 6.5%–38% in
biologic and immunologic agents, 7.1%–27.5% in 
hematological agents, and 8.1%–11.7% in systemic anti-
infectives.
CONCLUSION: There is considerable variation among
institutions in pharmacy costs, length of stay and mor-
tality. Further research into the drivers of pharmaceutical
cost variation, resource utilization and clinical outcome
is warranted.
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EVALUATION OF DRUGS IN A THREE-TIER
PRESCRIPTION DRUG BENEFIT CO-PAYMENT
PRICING STRUCTURE
Patel G, Shah S, Siganga W, Lively B, Holiday-Goodman M
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One of the widely used pharmacy beneﬁt management
tools, to control drug expenditures, is three-tier drug 
co-payment.
OBJECTIVES: This study examines the effect of the
three-tier drug co-payment, for the individual plan
sponsor, on Per Member Per Month (PMPM) ingredient
costs, PMPM utilization and ingredient cost per pre-
scription of the preferred and non-preferred drugs.
METHODS: Prescription records, from January 1, 1999
to December 31, 2000 for members enrolled in a three-
